文献速递胃肠动力与功能性疾病

系统综述与Meta分析:粪菌移植治疗肠易激综合征的疗效

Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome.
PubMed 文献 · Aliment Pharmacol Ther · 2019-05-28

该系统综述与Meta分析检索至2019年3月的数据库,纳入5项随机对照试验共267例肠易激综合征(IBS)患者,比较粪菌移植(FMT)与安慰剂的疗效。总体汇总显示IBS症状未改善的相对风险(RR)为0.98(95%CI 0.58-1.66);口服安慰剂胶囊优于供体粪便胶囊(RR=1.96;95%CI 1.19-3.20),而经结肠镜或鼻空肠管给予供体粪便可能有益。结论认为经结肠镜或鼻空肠管给予新鲜或冷冻供体粪便可能对IBS有益,需更大规模、更严谨的试验。

要点

  • 总体汇总5项RCT共267例IBS患者,FMT与安慰剂相比症状未改善的RR为0.98(95%CI 0.58-1.66)。
  • 口服安慰剂胶囊优于供体粪便胶囊(RR=1.96;95%CI 1.19-3.20)。
  • 经结肠镜给予供体粪便优于自体粪便(RR=0.63;95%CI 0.43-0.93),经鼻空肠管呈获益趋势(RR=0.69;95%CI 0.46-1.02)。

核心结论

  • 经结肠镜或鼻空肠管给予新鲜或冷冻供体粪便可能对IBS有益。
  • 需要更大规模、更严谨的FMT治疗IBS试验。

研究设计与样本

  • 系统综述与Meta分析,检索MEDLINE、EMBASE、EMBASE Classic、Cochrane对照试验中心注册库及clinicaltrials.gov至2019年3月。
  • 纳入比较FMT与安慰剂、招募成人IBS患者的随机对照试验,共5项RCT、267例患者。
  • 纳入患者中92.2%为IBS-D或IBS-M,仅7.8%为IBS-C。

主要发现

  • 所有患者不分粪便类型汇总,IBS症状未改善的RR为0.98(95%CI 0.58-1.66)。
  • 两项汇总试验中,口服安慰剂胶囊优于含供体粪便胶囊(RR=1.96;95%CI 1.19-3.20)。
  • 两项汇总RCT中,经结肠镜给予供体粪便优于自体粪便(RR=0.63;95%CI 0.43-0.93)。
  • 一项试验中,经鼻空肠管给予供体粪便相比自体粪便呈获益趋势(RR=0.69;95%CI 0.46-1.02)。

关键数值与推荐

  • 总体汇总IBS症状未改善的RR为0.98(95%CI 0.58-1.66)。
  • 口服安慰剂胶囊 vs 供体粪便胶囊:RR=1.96(95%CI 1.19-3.20)。
  • 经结肠镜供体粪便 vs 自体粪便:RR=0.63(95%CI 0.43-0.93)。
  • 经鼻空肠管供体粪便 vs 自体粪便:RR=0.69(95%CI 0.46-1.02)。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 需要更大规模、更严谨的FMT治疗IBS试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Increasing evidence supports the role of the gut microbiota in the aetiology of irritable bowel syndrome (IBS). Faecal microbiota transplantation (FMT) is a highly effective treatment against recurrent Clostridioides difficile infection in randomised controlled trials (RCTs), and may be beneficial in ulcerative colitis. However, its efficacy in IBS is uncertain. AIM: To perform a systematic review and meta-analysis to examine this issue. METHODS: We searched MEDLINE, EMBASE, EMBASE Classic, the Cochrane Central Register of Controlled Trials, and clinicaltrials.gov through to March 2019. RCTs recruiting adults with IBS, which compared FMT with placebo, were eligible. Dichotomous symptom data were pooled to obtain a relative risk (RR) of remaining symptomatic after therapy, with a 95% CI. RESULTS: The search strategy identified 322 citations. Five RCTs were eligible for inclusion, containing 267 patients. Overall, 92.2% of included patients had IBS-D or IBS-M, and only 7.8% IBS-C. When data were pooled for all patients, irrespective of stool type, the RR of IBS symptoms not improving was 0.98 (95% CI 0.58-1.66). Placebo capsules administered orally were superior to capsules containing donor stool in two pooled trials (RR = 1.96; 95% CI 1.19-3.20). FMT from donor stool delivered via colonoscopy was superior to autologous stool in two pooled RCTs (RR = 0.63; 95% CI 0.43-0.93). FMT from donor stool via nasojejunal tube showed a trend towards a benefit over autologous stool in one trial (RR = 0.69; 95% CI 0.46-1.02). CONCLUSIONS: Fresh or frozen donor stool delivered via colonoscopy or nasojejunal tube may be beneficial in IBS. Larger, more rigorously conducted trials of FMT in IBS are needed.

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Ianiro G, Eusebi LH, Black CJ, et al. Systematic review with meta-analysis: efficacy of faecal microbiota transplantation for the treatment of irritable bowel syndrome. Aliment Pharmacol Ther. 2019. PMID: 31136009. doi:10.1111/apt.15330

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。